Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
MorphoSys AG
MorphoSys AG
Activities:
Ingredients
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Research & Development
MorphoSys and Immatics Biotechnologies sign immuno-oncology agreement
To develop antibody based therapies against multiple cancers
Research & Development
Merck Serono and MorphoSys agree immuno-oncology collaboration
MorphoSys\' Ylanthia antibody technology will be used to identify antibodies to fight tumours
Research & Development
MorphoSys and Heptares to develop antibody therapeutics targeting GPCRs
MorphoSys will apply Ylanthia library to develop products against StaRs from Heptares
Research & Development
MorphoSys expands 10-year antibody alliance with Novartis
Long-standing agreement will benefit from technologies not available in 2007
Ingredients
MorphoSys makes two management appointments
Charlotte Lohmann and Martin Clark join the German firm
Ingredients
MorphoSys unveils new antibody technology
Ylanthia will show higher success rates and shorter timelines in antibody drug development
Manufacturing
Boehringer signs manufacturing agreement with MorphoSys
Covers process development and manufacturing of clinical material for MOR208 antibody
Subscribe now